SCHEMBL2977952

SCHEMBL2977952

COCc1ccc2c(c1)ncn2-c1cccc(C(C)OCc2ncc[nH]2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.37
FGFR1 P11362 12/20 0.37
SRC P12931 3/20 0.36
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRA5 P31644 2/20 0.35
GABRA3 P34903 2/20 0.35
GABRA2 P47869 2/20 0.35
GABRB2 P47870 2/20 0.35
GABRA4 P48169 2/20 0.35
GABRE P78334 2/20 0.35
GABRA6 Q16445 2/20 0.35
GABRG1 Q8N1C3 2/20 0.35
GABRG3 Q99928 2/20 0.35
GABRQ Q9UN88 2/20 0.35
KIT P10721 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2974099 0.91 HPGD (0.39) HPGDFGFR1SRCGABRPGABRD
SCHEMBL2653928 0.91 GABRP (0.40) HPGDFGFR1SRCGABRPGABRD
SCHEMBL2652210 0.87 HPGD (0.42) HPGDFGFR1SRCGABRPGABRD
SCHEMBL2978344 0.86 HPGD (0.39) HPGDFGFR1KITFLT3MAPK1
SCHEMBL2653523 0.85 FGFR1 (0.43) HPGDFGFR1SRCGABRPGABRD
SCHEMBL2977950 0.84 FGFR1 (0.39) FGFR1SRCGABRA1GABRG2GABRB3
SCHEMBL2652698 0.83 HPGD (0.38) HPGDFGFR1SRCGABRPGABRD
SCHEMBL2652428 0.81 HPGD (0.45) HPGDFGFR1GABRA1GABRG2GABRB3
SCHEMBL2976805 0.76 PRKCI (0.44) FGFR1SRCGABRPGABRDGABRA1
SCHEMBL2974092 0.76 FGFR1 (0.38) HPGDFGFR1SRCGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 HPGD 1855/4885FGFR1 4324/4885SRC 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.